March 2 (Reuters) - UniQure said on Monday the U.S. health regulator has informed the company that data from an early- to mid-stage trial of its gene therapy for a brain disorder would not support a
FDA calls for fresh study of uniQure's Huntington's gene therapy, shares slide
By Puyaan Singh and Christy Santhosh
FDA Requests New Study and Market Impact
March 2 (Reuters) - UniQure said the U.S. drug regulator called for a new study to support the approval of its gene therapy for a brain disorder as the data from a previous trial was insufficient, sending the Dutch drugmaker's U.S.-listed shares more than 36% lower on Monday.
Shares have been under pressure since November, when the U.S. Food and Drug Administration said the data likely would not support an accelerated approval application.
Details of AMT‑130 and FDA Recommendations
The company's drug for Huntington's disease, named AMT‑130, is administered after neurosurgery directly into the brain's striatum.
FDA's Study Design Suggestions
The FDA strongly recommended to uniQure a study that randomly assigns patients to get either the therapy or a sham procedure, which may "superficially drill a hole on the skull," said medical chief Walid Abi-Saab on Monday.
This is risky as these patients would not receive AMT-130 while their disease worsens, he said.
Concerns Raised by FDA and Analysts
FDA Commissioner Dr. Marty Makary last week criticized a drug requiring a "burr hole" in the skull, without naming it or the company, but Wall Street analysts feared the comment referred to AMT‑130.
Analyst Perspectives
Leerink analyst Joseph Schwartz said that it seems contradictory for the FDA to be concerned about the morbidity associated with burr holes but still want a sham control arm.
Background on Huntington's Disease and Trial Data
Huntington's disease is a fatal inherited neurodegenerative disorder with no approved therapies that slow progression.
Last year, the company reported trial data showing AMT-130 slowed progression by 75%.
Future Outlook and Industry Implications
Potential Delays and Ethical Concerns
PATH FORWARD WILL LIKELY TAKE YEARS
Wall Street analysts pointed to ethical concerns about the FDA-recommended study and warned that the delay could cost the company its first-mover advantage to rivals developing late‑stage candidates, such as PTC's votoplam, an oral drug that does not require neurosurgery.
Financial and Competitive Impact
A study would likely be costly and a data readout would be multiple years away, said Barclays analyst Eliana Merle.
(Reporting by Puyaan Singh in Bengaluru; Editing by Shilpi Majumdar and Sahal Muhammed)
